HK1203949A1 - Inhibitors of iap iap - Google Patents

Inhibitors of iap iap

Info

Publication number
HK1203949A1
HK1203949A1 HK15104538.4A HK15104538A HK1203949A1 HK 1203949 A1 HK1203949 A1 HK 1203949A1 HK 15104538 A HK15104538 A HK 15104538A HK 1203949 A1 HK1203949 A1 HK 1203949A1
Authority
HK
Hong Kong
Prior art keywords
iap
inhibitors
iap iap
Prior art date
Application number
HK15104538.4A
Other languages
English (en)
Chinese (zh)
Inventor
‧科昂
‧加扎德
‧徐
‧弗吕加勒
Original Assignee
Curisinc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curisinc, Genentech Inc filed Critical Curisinc
Publication of HK1203949A1 publication Critical patent/HK1203949A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0812Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0815Tripeptides with the first amino acid being basic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK15104538.4A 2012-01-03 2015-05-13 Inhibitors of iap iap HK1203949A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261582760P 2012-01-03 2012-01-03
PCT/US2013/020124 WO2013103703A1 (en) 2012-01-03 2013-01-03 Inhibitors of iap

Publications (1)

Publication Number Publication Date
HK1203949A1 true HK1203949A1 (en) 2015-11-06

Family

ID=48695302

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15104538.4A HK1203949A1 (en) 2012-01-03 2015-05-13 Inhibitors of iap iap

Country Status (41)

Country Link
US (6) US8716236B2 (pl)
EP (2) EP2800749B1 (pl)
JP (2) JP5747137B2 (pl)
KR (3) KR101553792B1 (pl)
CN (2) CN107915728B (pl)
AR (2) AR089623A1 (pl)
AU (1) AU2013202780B2 (pl)
BR (1) BR112014016637B1 (pl)
CA (1) CA2861637C (pl)
CL (1) CL2014001770A1 (pl)
CO (1) CO7020915A2 (pl)
CR (1) CR20140367A (pl)
CY (2) CY1118371T1 (pl)
DK (2) DK3133073T3 (pl)
EC (1) ECSP14011792A (pl)
ES (2) ES2672809T3 (pl)
HK (1) HK1203949A1 (pl)
HR (2) HRP20161381T1 (pl)
HU (2) HUE031305T2 (pl)
IL (2) IL242314A (pl)
LT (2) LT3133073T (pl)
MA (1) MA35895B1 (pl)
ME (2) ME02526B (pl)
MX (1) MX336294B (pl)
MY (1) MY178390A (pl)
NO (1) NO2755614T3 (pl)
NZ (1) NZ627480A (pl)
PE (1) PE20142182A1 (pl)
PH (2) PH12014501534B1 (pl)
PL (2) PL3133073T3 (pl)
PT (2) PT3133073T (pl)
RS (2) RS57438B1 (pl)
RU (2) RU2593259C2 (pl)
SG (1) SG11201403784QA (pl)
SI (2) SI2800749T1 (pl)
SM (1) SMT201600357B (pl)
TR (1) TR201808088T4 (pl)
TW (1) TWI503318B (pl)
UA (1) UA114417C2 (pl)
WO (1) WO2013103703A1 (pl)
ZA (1) ZA201405535B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2755614T3 (pl) * 2012-01-03 2018-03-31
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
CN109705191B (zh) * 2017-10-25 2022-04-29 广东东阳光药业有限公司 Iap抑制剂及其在药物中的应用
SG11202004377XA (en) * 2017-11-13 2020-06-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Smac mimetics used as iap inhibitors and use thereof
WO2020027225A1 (ja) 2018-07-31 2020-02-06 ファイメクス株式会社 複素環化合物
WO2021020585A1 (ja) 2019-07-31 2021-02-04 ファイメクス株式会社 複素環化合物
CN112972684B (zh) * 2019-12-02 2024-05-31 苏州亚盛药业有限公司 Iap抑制剂与parp或mek抑制剂或其他化学治疗剂的组合
KR20220130190A (ko) 2020-01-20 2022-09-26 아스트라제네카 아베 암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제
WO2023239422A2 (en) 2021-10-22 2023-12-14 University Of Houston System Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
ATE297904T1 (de) 1997-04-15 2005-07-15 Genentech Inc Halo-alkoxycarbonylverbindungen
ES2524449T3 (es) * 2004-07-02 2014-12-09 Genentech, Inc. Inhibidores de IAP
CN101146803A (zh) * 2004-12-20 2008-03-19 健泰科生物技术公司 Iap的吡咯烷抑制剂
BRPI0719221A2 (pt) 2006-10-12 2014-03-18 Novartis Ag Derivados de pirrolidina como inibidores de iap
TWI432212B (zh) 2007-04-30 2014-04-01 Genentech Inc Iap抑制劑
NO2755614T3 (pl) 2012-01-03 2018-03-31
USD690416S1 (en) 2012-12-12 2013-09-24 Pharmajet, Inc. Needle-free syringe

Also Published As

Publication number Publication date
HRP20161381T1 (hr) 2016-12-02
MY178390A (en) 2020-10-12
HUE031305T2 (hu) 2017-07-28
US9586991B2 (en) 2017-03-07
ES2672809T3 (es) 2018-06-18
EP3133073B1 (en) 2018-05-02
US20160102119A1 (en) 2016-04-14
NZ627480A (en) 2016-04-29
ME03084B (me) 2019-01-20
US20190224269A1 (en) 2019-07-25
US20130172264A1 (en) 2013-07-04
PL2800749T3 (pl) 2017-01-31
KR20140107670A (ko) 2014-09-04
PE20142182A1 (es) 2015-01-16
LT3133073T (lt) 2018-06-25
ECSP14011792A (es) 2015-12-31
CR20140367A (es) 2015-02-18
ES2594856T3 (es) 2016-12-23
CY1118371T1 (el) 2017-06-28
CY1120355T1 (el) 2019-07-10
BR112014016637A2 (pt) 2017-06-13
US20220211797A1 (en) 2022-07-07
HRP20180976T1 (hr) 2018-08-10
KR20150065960A (ko) 2015-06-15
US11963994B2 (en) 2024-04-23
EP2800749A1 (en) 2014-11-12
JP2015504072A (ja) 2015-02-05
DK2800749T3 (en) 2016-11-07
US9238675B2 (en) 2016-01-19
RU2016124658A (ru) 2018-12-04
IL242314A (en) 2016-08-31
PH12015501038A1 (en) 2015-09-21
KR101917992B1 (ko) 2018-11-13
US11096982B2 (en) 2021-08-24
MX336294B (es) 2016-01-14
AU2013202780A1 (en) 2013-07-18
NO2755614T3 (pl) 2018-03-31
EP3133073A2 (en) 2017-02-22
EP3133073A3 (en) 2017-03-22
CO7020915A2 (es) 2014-08-11
US8716236B2 (en) 2014-05-06
CN107915728A (zh) 2018-04-17
PH12014501534A1 (en) 2014-10-08
MX2014007895A (es) 2015-03-19
AU2013202780B2 (en) 2015-04-16
DK3133073T3 (en) 2018-06-18
UA114417C2 (uk) 2017-06-12
SI3133073T1 (en) 2018-06-29
RS55327B1 (sr) 2017-03-31
CN104159897A (zh) 2014-11-19
PH12015501038B1 (en) 2015-09-21
PT3133073T (pt) 2018-06-18
IL233386A (en) 2016-08-31
CL2014001770A1 (es) 2015-04-17
AR123542A2 (es) 2022-12-14
CA2861637C (en) 2017-07-18
TWI503318B (zh) 2015-10-11
RU2593259C2 (ru) 2016-08-10
BR112014016637B1 (pt) 2022-06-14
AR089623A1 (es) 2014-09-03
RU2728789C2 (ru) 2020-07-31
ZA201405535B (en) 2017-08-30
SI2800749T1 (sl) 2016-11-30
KR20180051646A (ko) 2018-05-16
EP2800749B1 (en) 2016-09-21
IL233386A0 (en) 2014-08-31
MA35895B1 (fr) 2014-12-01
JP2015199738A (ja) 2015-11-12
CA2861637A1 (en) 2013-07-11
ME02526B (me) 2017-02-20
RU2016124658A3 (pl) 2019-09-09
PH12014501534B1 (en) 2014-10-08
BR112014016637A8 (pt) 2017-07-04
US20140235551A1 (en) 2014-08-21
PL3133073T3 (pl) 2018-09-28
JP5747137B2 (ja) 2015-07-08
EP2800749A4 (en) 2015-08-05
PT2800749T (pt) 2016-10-24
SMT201600357B (it) 2016-11-10
RU2014130171A (ru) 2016-02-27
SG11201403784QA (en) 2014-08-28
HUE037760T2 (hu) 2018-09-28
TW201333001A (zh) 2013-08-16
TR201808088T4 (tr) 2018-06-21
WO2013103703A1 (en) 2013-07-11
RS57438B1 (sr) 2018-09-28
US20170136084A1 (en) 2017-05-18
CN107915728B (zh) 2021-04-30
KR101553792B1 (ko) 2015-09-16
KR101855566B1 (ko) 2018-05-04
LT2800749T (lt) 2016-10-25

Similar Documents

Publication Publication Date Title
EP2920149A4 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS ROR-GAMMA-T-HEMMER AND USES THEREOF
AP4029A (en) Inhibitors of beta-secretase
HK1203949A1 (en) Inhibitors of iap iap
HK1211024A1 (en) Inhibitors of syk syk
HK1209422A1 (en) Fbxo3 inhibitors fbxo3
IL236963A0 (en) beta-secretase inhibitors
IL240763A0 (en) The halopyrazoles as thrombin inhibitors
PL2888228T3 (pl) Inhibitory oddziaływania CD40-TRAF6
EP2892529A4 (en) USES OF (-) - PERHEXILINE
GB201215942D0 (en) Method of treatent
EP2879681A4 (en) INDOINDUBSTITUTED PYRROLOPYRIMIDINYL HIBITORS OF UBA6
ZA201503833B (en) Method of hemoglobin-f determination